SHSE:603676 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SHSE:603676 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Xizang Weixinkang Pharmaceutical Co's Enterprise Value is ¥3,129 Mil. Xizang Weixinkang Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was ¥315 Mil. Therefore, Xizang Weixinkang Pharmaceutical Co's EV-to-FCF for today is 9.94.
The historical rank and industry rank for Xizang Weixinkang Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
During the past 11 years, the highest EV-to-FCF of Xizang Weixinkang Pharmaceutical Co was 1678.02. The lowest was -593.57. And the median was 25.53.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2025-01-18), Xizang Weixinkang Pharmaceutical Co's stock price is ¥9.60. Xizang Weixinkang Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥0.570. Therefore, Xizang Weixinkang Pharmaceutical Co's PE Ratio (TTM) for today is 16.84.
The historical data trend for Xizang Weixinkang Pharmaceutical Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xizang Weixinkang Pharmaceutical Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-FCF | Get a 7-Day Free Trial | 63.15 | 40.75 | 29.06 | 36.37 | 21.44 |
Xizang Weixinkang Pharmaceutical Co Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-FCF | Get a 7-Day Free Trial | 26.21 | 21.44 | 10.95 | 8.26 | 9.16 |
For the Drug Manufacturers - Specialty & Generic subindustry, Xizang Weixinkang Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Xizang Weixinkang Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Xizang Weixinkang Pharmaceutical Co's EV-to-FCF falls into.
Xizang Weixinkang Pharmaceutical Co's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 3129.416 | / | 314.929 | |
= | 9.94 |
Xizang Weixinkang Pharmaceutical Co's current Enterprise Value is ¥3,129 Mil.
Xizang Weixinkang Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥315 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xizang Weixinkang Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 9.60 | / | 0.570 | |
= | 16.84 |
Xizang Weixinkang Pharmaceutical Co's share price for today is ¥9.60.
Xizang Weixinkang Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Xizang Weixinkang Pharmaceutical Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Weng Zi Zhong | senior management | |
Chen Shi Gong | Directors, senior managers | |
Zhou Xiao Bing | senior management | |
Liu Feng | Directors, senior managers | |
Yu Hai Bo | senior management | |
Zhang Hong | Directors, senior managers | |
Zheng Yan Xia | senior management | |
Wen Xiao Quan | Director |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.